Herpes Simplex Clinical Trial
OBJECTIVES:
I. Determine the efficacy of long term suppressive therapy with oral acyclovir in infants
with herpes simplex virus infection limited to skin, eyes, and mouth.
II. Determine the neurologic outcome in these patients when treated with this regimen.
III. Evaluate the significance of a positive cerebrospinal fluid (CSF) polymerase chain
reaction (PCR) result when all other CSF parameters remain normal in these patients.
IV. Correlate the time to first positive CSF PCR result in the first 12 months of life with
clinical neurological assessment in these patients when treated with this regimen.
V. Determine whether the continuous administration of this drug suppresses recurrent skin
lesions in these patients.
VI. Determine the safety of this regimen in these patients.
PROTOCOL OUTLINE:
This is a randomized, double blind, placebo controlled, multicenter study.
All patients undergo a lumbar puncture and then receive acyclovir IV every 8 hours on Days
1-14. On Day 12, patients may undergo a lumbar puncture (at discretion of investigator).
Whole blood is obtained for herpes simplex virus PCR analysis. Upon completion of
intravenous therapy, patients with a negative CSF PCR are randomized to one of two treatment
arms.
Arm I: Patients receive oral acyclovir three times daily for 6 months.
Arm II: Patients receive placebo three times daily for 6 months.
In case of cutaneous recurrence during the first 12 months of the study, patients receive
open label oral acyclovir (if CSF PCR is negative) or acyclovir IV (if CSF PCR is positive)
for 5 days. Patients may or may not continue on study drug following this treatment.
Patients are followed at 6, 12, 24, 36, 48, and 60 months of age.
;
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05468619 -
Neonatal Phase 1 Valacyclovir Study
|
Phase 1 | |
| Withdrawn |
NCT02349828 -
Antiviral Prophylaxis in a Burn Population
|
Phase 2/Phase 3 | |
| Recruiting |
NCT01176409 -
Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?
|
Phase 3 | |
| Completed |
NCT04664127 -
Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
|
||
| Completed |
NCT00448227 -
Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection
|
Phase 2 | |
| Completed |
NCT00000139 -
Herpetic Eye Disease Study (HEDS) II
|
Phase 3 | |
| Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
| Completed |
NCT02209324 -
Open-label Study of ASP2151 in Herpes Simplex Patients
|
Phase 3 | |
| Completed |
NCT00855309 -
Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia
|
Phase 3 | |
| Completed |
NCT01602562 -
Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients
|
Phase 3 | |
| Completed |
NCT00973466 -
Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients
|
N/A | |
| Completed |
NCT00698893 -
Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults
|
Phase 1 | |
| Active, not recruiting |
NCT05298254 -
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03178747 -
Tzanck Smear With Methylene Blue Stain for Herpes
|
Phase 3 | |
| Completed |
NCT00164424 -
Episodic Acyclovir Therapy for Genital Ulcers
|
Phase 2/Phase 3 | |
| Completed |
NCT00161434 -
A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons
|
Phase 4 | |
| Terminated |
NCT04762511 -
A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years
|
Phase 1 | |
| Completed |
NCT00699764 -
Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease
|
Phase 3 | |
| Recruiting |
NCT04065971 -
Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections.
|
Phase 4 | |
| Active, not recruiting |
NCT00005663 -
A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients
|
Phase 3 |